[Federal Register Volume 87, Number 37 (Thursday, February 24, 2022)]
[Notices]
[Pages 10332-10333]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03896]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-04-2022]


Foreign-Trade Zone (FTZ) 177--Evansville, Indiana; Notification 
of Proposed Production Activity; AstraZeneca Pharmaceuticals, LP; 
(Pharmaceutical Products); Mount Vernon, Indiana

    AstraZeneca Pharmaceuticals, LP submitted a notification of 
proposed production activity to the FTZ Board (the Board) for its 
facility in Mount Vernon, Indiana within Subzone 177A. The notification 
conforming to the requirements of the Board's regulations (15 CFR 
400.22) was received on February 14, 2022.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status materials and specific finished 
products described in the submitted notification (summarized below) and 
subsequently authorized by the Board. The benefits that may stem from 
conducting production activity under FTZ procedures are explained in 
the background section of the Board's website--accessible via 
www.trade.gov/ftz. The proposed finished products and materials would 
be added to the production authority that the Board previously approved 
for the operation, as reflected on the Board's website.
    The proposed finished products include: ARIMIDEX (anastrozole) 
tablets; BRILINTA (ticagrelor) tablets; CRESTOR (rosuvastatin calcium) 
tablets; LYNPARZA (olaparib) tablets; SEROQUEL IR (quetiapine fumarate) 
tablets; and, SEROQUEL XR (quetiapine fumarate) tablets (duty-free).
    The proposed foreign-status materials include: Anastrozole active 
pharmaceutical ingredient (API); microcrystalline cellulose; olaparib 
API; quetiapine fumarate API; rosuvastatin calcium API; and, ticagrelor 
API (duty rate ranges from 5.2% to 6.5%). The request indicates that 
olaparib API and ticagrelor API are subject to duties under Section 301 
of the Trade Act of 1974 (Section 301), depending on the country of 
origin. The applicable Section 301 decisions require subject 
merchandise to be admitted to FTZs in privileged foreign status (19 CFR 
146.41).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is April 5, 2022.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Christopher Wedderburn at 
[email protected].


[[Page 10333]]


    Dated: February 17, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022-03896 Filed 2-23-22; 8:45 am]
BILLING CODE 3510-DS-P